Witnessing the stock’s movement on the chart, on Thursday, Idexx Laboratories, Inc (NASDAQ: IDXX) set off with pace as it heaved 1.16% to $422.54, before settling in for the price of $417.71 at the close. Taking a more long-term approach, IDXX posted a 52-week range of $398.50-$548.88.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 10.23%. Meanwhile, its Annual Earning per share during the time was 16.90%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 12.26%. This publicly-traded company’s shares outstanding now amounts to $81.60 million, simultaneously with a float of $80.49 million. The organization now has a market capitalization sitting at $34.24 billion. At the time of writing, stock’s 50-day Moving Average stood at $436.89, while the 200-day Moving Average is $456.86.
Idexx Laboratories, Inc (IDXX) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Diagnostics & Research industry. Idexx Laboratories, Inc’s current insider ownership accounts for 1.03%, in contrast to 89.82% institutional ownership. According to the most recent insider trade that took place on Feb 10 ’25, this organization’s Executive Vice President sold 9,986 shares at the rate of 462.53, making the entire transaction reach 4,618,862 in total value, affecting insider ownership by 8,176.
Idexx Laboratories, Inc (IDXX) Earnings and Revenue Records
Idexx Laboratories, Inc’s EPS increase for this current 12-month fiscal period is 12.26% and is forecasted to reach 13.57 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 13.04% through the next 5 years, which can be compared against the 16.90% growth it accomplished over the previous five years trading on the market.
Idexx Laboratories, Inc (NASDAQ: IDXX) Trading Performance Indicators
Let’s observe the current performance indicators for Idexx Laboratories, Inc (IDXX). It’s Quick Ratio in the last reported quarter now stands at 0.90. The Stock has managed to achieve an average true range (ATR) of 11.00. Alongside those numbers, its PE Ratio stands at $39.62, and its Beta score is 1.52. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 8.79. Similarly, its price to free cash flow for trailing twelve months is now 42.37.
In the same vein, IDXX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 10.67, a figure that is expected to reach 2.86 in the next quarter, and analysts are predicting that it will be 13.57 at the market close of one year from today.
Technical Analysis of Idexx Laboratories, Inc (IDXX)
Going through the that latest performance of [Idexx Laboratories, Inc, IDXX]. Its last 5-days volume of 0.79 million indicated improvement to the volume of 0.73 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 50.64% While, its Average True Range was 10.11.
Raw Stochastic average of Idexx Laboratories, Inc (IDXX) in the period of the previous 100 days is set at 31.56%, which indicates a major fall in contrast to 41.88% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 24.45% that was lower than 33.28% volatility it exhibited in the past 100-days period.
